
A new drug combination has shown promise as a first-line treatment for patients with metastatic pancreatic cancer. Daraxonrasib, a RAS inhibitor, combined with chemotherapy, demonstrated encouraging results in an early-stage trial.
The study, presented at the EORTC-NCI-AACR Symposium, involved 61 patients with metastatic pancreatic adenocarcinoma (PDAC). The combination therapy achieved a 61% objective response rate, with 8.2% of patients experiencing a complete response. The median duration of response was 11.1 months.
Survival Rates Show Improvement
Researchers reported a median progression-free survival (PFS) of 12.8 months, and a 12-month PFS rate of 51.7%. The overall survival (OS) rate at 12 months reached 76.6%, exceeding the typical 8.5 to 11.1 months associated with standard chemotherapy.
Wungki Park, MD, from the Memorial Sloan Kettering Cancer Center, called these findings a “potentially transformative advance” in treating this aggressive cancer.
Focusing on a Key Cancer Driver
This treatment targets RAS, a mutated protein that fuels most pancreatic cancers. Shivan Sivakumar, PhD, of the University of Birmingham, highlighted the potential to move beyond chemotherapy as the primary treatment option.
Sivakumar stated that this approach could enhance outcomes by directly tackling a root cause of the disease.
However, the study’s limited size and absence of a randomized control group necessitate caution. Larger trials, such as the ongoing phase III RASolute 303, are key for confirmation.
Earlier Success and Side Effects
Daraxonrasib previously proved effective in the phase III RASolute 302 trial, leading to its FDA approval for patients with previously treated metastatic PDAC.
In the current study, 75% of participants experienced grade 3 or higher adverse events, including anemia, fatigue, and reduced neutrophil counts. While dose adjustments were frequent, only 5% of patients discontinued treatment due to side effects.
Participants in the trial had a median age of 67, with 59% being men. Most had liver metastases and stage IV disease at the start. They received 200 mg of daraxonrasib daily, along with gemcitabine and nab-paclitaxel every 28 days.
FDA Approval and Ongoing Trials
The FDA approved the drug in August for patients who have had at least one prior systemic therapy or are ineligible for multi-agent systemic therapy. This followed an expanded access program earlier in the year.
An ongoing phase I/II multicenter trial, RMC-GI-102, is investigating the drug in patients with RAS-mutant gastrointestinal tumors.
Serious treatment-related adverse events occurred in 23% of patients, with dose modifications due to adverse events in 66% of patients, primarily for rash. Treatment discontinuation due to adverse events was rare, at 5%.